Navigation Links
Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
Date:11/13/2008

EAST BRUNSWICK, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Christopher Clement, President and Chief Executive Officer of Savient Pharmaceuticals will present a corporate update at the upcoming Lazard Capital Markets 5th Annual Healthcare Conference.

The presentation is scheduled to begin on Tuesday, November 18, 2008 at 9:25 a.m. ET. The Conference will be held at the St. Regis Hotel in New York City November 18-19, 2008.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007 and the BLA was filed with the FDA in October 2008. Savient has exclusively licensed worldwide rights to the technology related to pegloticase, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
2. Savient Submits Biologics License Application (BLA) for pegloticase
3. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
4. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
5. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
6. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
7. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... April 12, 2011 Drs. Rodney Landreneau and ... non small cell lung cancer study at the 2011 Society ... Landreneau is Director of the Lung Center at UPMC Shady ... at UPMC Passavant Medical Center and Director of the Division ...
... 12, 2011 Biotech Medical, Inc. is set to ... SpectraSan™ "Hungry Enzymes". The products will be available for ... a Pet Stain & Odor Eraser, Spa & Whirlpool ... All-Purpose Cleaner & Degreaser, Glass & Stainless Steel Cleaner ...
... Dr. Fresh®, Inc., maker of the popular FireFly® children,s ... to raise awareness and funds for Smile Train, the ... company will donate $1 for every new "Like" on ... Smile Train.  The organization provides life-changing surgery for poor ...
Cached Biology Technology:Precision Therapeutics' ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer 2Biotech Medical, Inc. Introduces a Full Line of Enzyme Cleaners 2FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train 2
(Date:4/17/2014)... have hit on a novel method to help ... and most effective treatment possible., Kidney stones represent ... developing world. If left untreated, apart from being ... and other complications. In many patients treated successfully, ... more effective pathological approach to diagnosis and treatment ...
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... University researchers have detected new early-warning signs of the ... could have far-reaching implications for the diagnosis and treatment ... 25 million Americans. , "We had not expected to ... early stages," said Ann Elsner, professor and associate dean ... of the study. "We set out to study the ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Gary Hoyle, PhD, professor, University of Louisville School of ... research to develop an effective medical treatment to counteract ... of terrorism. The National Institute of Environmental Health Sciences ... have awarded Hoyle $2.6 million over five-years to further ...
... in the southeastern United States, and for scientists trying to ... ) is not cooperating. So far botanists have ... plant to boiling water, dry heat up to 284 degrees ... coax them into germination. Nothing has worked. "Complete ...
... and conservation successes in the face of rapid environmental ... plants adapt to local climate. To improve scientists, ... 7, 2011 issue of Science helps define ... The National Science Foundation partly funded the study, ...
Cached Biology News:UofL researcher awarded $2.6 million NIH grant renewal 2Super-tough seed coat keeps Michaux's sumac on critically endangered list 2